Chronic erythema nodosum leprosum in Hansen's disease: a challenging clinical management.

Trans R Soc Trop Med HygNov 3, 2026

Michele Spinicci, Anna Barbiero, Tommaso Manciulli et al.

✦ AI-curated · Sources linked

Case in brief

A 34-year-old Moroccan man with multibacillary Hansen’s disease developed chronic erythema nodosum leprosum (ENL), with recurrent systemic and cutaneous flares requiring prolonged immunomodulatory treatment. Corticosteroids, thalidomide, azathioprine, methotrexate, and anti-TNF-α therapy each provided incomplete control. After six years of recurrent disease and several hospitalizations, a regimen of methylprednisolone, high-dose thalidomide, and clofazimine achieved sustained remission, permitting gradual discontinuation of treatment.

What made this case unusual

Despite trials of multiple immunomodulatory agents, including anti-TNF-α therapy, control remained incomplete until the combination of methylprednisolone, high-dose thalidomide, and clofazimine was used.

Diagnostic / clinical pearl

Chronic ENL can remain difficult to control despite several immunomodulatory approaches; this case describes sustained remission with combined methylprednisolone, high-dose thalidomide, and clofazimine.

Source

Published in Trans R Soc Trop Med Hyg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Dermatology

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.